Replies to post #417689 on Amarin Corp Plc (AMRN)

[Number sleven]

Zip, No arguments. The primary focus of the study is cerebral blood flow. Secondary measures involve biomarkers in spinal fluid. My point is that the design of this study should produce analog results. These surrogate endpoints are effected or they aren't. I have done research into the clinical work that this trial is based on. What I found suggests a strong likelihood that the primary endpoint should be achieved. Secondary endpoints also have a good chance. Either way this is not the sort of trial that shows a "trend". The results should be conclusive yes or no.
Sleven,

[newman2021]

zip, in addition to reducing the inflammation in the cells, did we not find out that Vascepa reduces plaque buildup in the blood vessels? I think as it comes to the AZ disease, Vascepa can reduce the inflammation in the brain cells as well as reduce the amyloid buildup there as amyloid is a plaque here.... is my logic making sense? I think BRAVE study is going to be a success. When are we getting the preliminary results??